window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Biologics & Biosimilars

  • Biologics & Biosimilars,Clinical Trials,Manufacturing,Oncology,Research & Development

    Anixa Biosciences advances breast cancer vaccine toward Phase 2 with Cytovance manufacturing deal

    Anixa Biosciences is advancing its breast cancer vaccine programme towards [...]

    April 7, 2026
  • Biologics & Biosimilars,Biotech,Drug discovery,European biotech,Healthcare leadership,Movers & Shakers,Opthalmology,Research & Development

    Link Biologics appoints Niall Martin to board as TSG-6 pipeline advances towards clinic

    Link Biologics has appointed Niall Martin to its board as [...]

    February 25, 2026
  • Biologics & Biosimilars,Clinical studies,Dermatology,Pharmaceuticals and therapeutics

    Almirall meets guidance with 12.4% net sales growth and dermatology portfolio progress in 2025

    Almirall delivered net sales growth of 12.4% in 2025, surpassing [...]

    February 23, 2026
  • Biologics & Biosimilars,Clinical studies,Clinical Trials,Pharmaceuticals and therapeutics

    Abivax shows anti-fibrotic activity for obefazimod in IBD at ECCO 2026

    Abivax has presented new preclinical and clinical data for obefazimod [...]

    February 23, 2026
  • Biologics & Biosimilars,Biomanufacturing,Biotech,Clinical Development,Clinical Trials,Drug approval,Drug Development,FDA,Rare Diseases,Research & Development

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    February 19, 2026
  • Antibody drug conjugates,Biologics & Biosimilars,Biomanufacturing,CDMOs & Manufacturing,Drug Development,Research & Development,Technology and platforms

    Lonza expands bioconjugate capabilities at Oss site to support ADC development

    Lonza expands its Advanced Synthesis capabilities at Oss, integrating ADC [...]

    February 19, 2026
  • Biologics & Biosimilars,Clinical Development,Drug approval,FDA,Funding,Pharmaceuticals and therapeutics,Rare Diseases,Regulatory Affairs

    Hansa Biopharma reports 135% Q4 revenue growth and BLA submission for imlifidase

    Hansa Biopharma has reported a 135% increase in fourth-quarter revenue [...]

    February 13, 2026
  • Biologics & Biosimilars,Biotech,Clinical Development,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics,Research & Development

    Evogene and Shanghai Lishan Biopharmaceuticals enter exclusive licensing agreement for BMC128

    Evogene Ltd and Shanghai Lishan Biopharmaceuticals Co. have entered into [...]

    February 13, 2026
  • Biologics & Biosimilars,Clinical Development,Clinical Trials,Drug Development,Movers & Shakers,Orthapaedics,Rare Diseases

    Levicept appoints James Sandy as chief development officer to advance LEVI-04 for osteoarthritis

    Levicept has strengthened its executive team with the appointment of [...]

    February 4, 2026
  • Biologics & Biosimilars,Cell & Gene Therapy,Healthcare leadership,Manufacturing,Movers & Shakers,Pharmaceuticals and therapeutics

    iOrganBio appoints Karol Jarzabek as chief operating officer

    iOrganBio has appointed Karol Jarzabek as chief operating officer to [...]

    January 29, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top